Home
Resources
Publications
Fostamatinib Disodium Hexahydrate: A Novel Treatment for Adult Immune Thrombocytopenia

Fostamatinib Disodium Hexahydrate: A Novel Treatment for Adult Immune Thrombocytopenia

Ali McBride, Pratima Nayak, Yuliya Kreychman, Leslie Todd, Anne-Marie Duliege, Amit R Mehta

Am J Manag Care. 2019 Nov;25(19 Suppl):S347-S358.

PMID: 31809006

Abstract:

Immune thrombocytopenia (ITP) is an autoimmune disease associated with substantial heterogeneity and varying outcomes. Significant bleeding, including intracranial hemorrhage, is a persistent risk for patients with ITP, along with cardiovascular disease. ITP has also been associated with decreased patient functionality and quality of life. The primary goal of ITP therapy is to lower the risk of bleeding and associated complications by raising platelet counts to levels that provide adequate hemostasis with minimal treatment-related toxicity. Current first-line treatments include corticosteroids, as well as intravenous and anti-D immunoglobulin. Despite the availability of several second-line options, the need for additional treatment options that can provide a stable, long-term response with few adverse effects is critical and ongoing. Fostamatinib disodium hexahydrate is an oral spleen tyrosine kinase inhibitor that produces a rapid, durable response in patients who have failed one or other treatments. Additionally, fostamatinib is well tolerated, and adverse effects can be actively mitigated through dose reduction, dose interruption, or standard therapeutic approaches.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
CS35328	Nabam-d4 hexahydrate			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: